Kymera Therapeutics, Inc. $KYMR Shares Sold by Driehaus Capital Management LLC

Key Points

• Driehaus Capital Management LLC reduced its stake in Kymera Therapeutics by 15.9%, now holding 1,168,791 shares worth approximately $31.99 million after selling 221,581 shares.
• CEO Nello Mainolfi sold 30,000 shares for $1.47 million, resulting in a 4.34% decrease in his ownership, while a director significantly increased their stake by 12%.
• Kymera reported negative earnings, missing estimates with a loss of $0.95 per share and a revenue decline of 55.1% year-over-year.

Driehaus Capital Management LLC lowered its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 15.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,168,791 shares of the company's stock after selling 221,581 shares during the period. Driehaus Capital Management LLC owned about 1.79% of Kymera Therapeutics worth $31,990,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. State of Wyoming acquired a new stake in Kymera Therapeutics in the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. purchased a new position in shares of Kymera Therapeutics in the 4th quarter valued at about $55,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics in the 1st quarter valued at about $68,000. KBC Group NV increased its holdings in shares of Kymera Therapeutics by 15.2% in the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after acquiring an additional 328 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Kymera Therapeutics by 95.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock valued at $194,000 after acquiring an additional 2,350 shares during the last quarter.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock traded down $1.10 during mid-day trading on Thursday, reaching $42.20. 881,626 shares of the company were exchanged, compared to its average volume of 692,242. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $53.27. The firm's 50-day simple moving average is $43.39 and its two-hundred day simple moving average is $36.95. The firm has a market cap of $3.02 billion, a PE ratio of -12.16 and a beta of 2.17.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The company had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. During the same period in the previous year, the business posted ($0.58) earnings per share. The firm's revenue was down 55.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. The Goldman Sachs Group upgraded Kymera Therapeutics to a "strong-buy" rating in a report on Tuesday, July 15th. Wells Fargo & Company dropped their price objective on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating on the stock in a report on Thursday, June 26th. Oppenheimer reiterated an "outperform" rating and issued a $53.00 price objective (down previously from $56.00) on shares of Kymera Therapeutics in a report on Friday, June 27th. B. Riley upgraded Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price target on the stock in a research note on Wednesday, July 30th. Finally, BTIG Research restated a "buy" rating and set a $59.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of "Buy" and a consensus target price of $58.76.

Insider Buying and Selling

In related news, Director Bvf Partners L. P/Il acquired 317,167 shares of the firm's stock in a transaction on Monday, June 30th. The stock was bought at an average cost of $44.00 per share, with a total value of $13,955,348.00. Following the transaction, the director owned 2,798,795 shares of the company's stock, valued at $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 655,500 shares of Kymera Therapeutics stock in a transaction dated Monday, June 30th. The stock was acquired at an average cost of $44.00 per share, with a total value of $28,842,000.00. Following the completion of the acquisition, the director directly owned 6,117,295 shares in the company, valued at approximately $269,160,980. This trade represents a 12.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.01% of the stock is currently owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.